Add Formweb to your mobile device
Search results for:
leuprolide
leuprolide
Brand names: Eligard, Leuprolide Acetate, Lupron Depot, Lupron Depot-Ped
| Form | Strength |
|---|---|
| KIT, SUBCUTANEOUS | 1 mg/0.2 mL |
| POWDER FOR INJECTION, EXTENDED RELEASE, INTRAMUSCULAR | 3.75 mg/month; 7.5 mg/month; 11.25 mg/3 months; 11.25 mg/month; 15 mg/month; 22.5 mg/3 months; 30 mg/4 months |
Last updated: Jun. 9, 2025
- RCRA: Disposal
- RCRA: Management of Pharmaceutical Waste Policy
This medication is Inpatient Non-formulary and Restricted to Outpatient Use. Inpatient use requires approval by a physician department leader (i.e. Medical Director or Chair, or hospital CMO) collaborating with a pharmacy leader. Note: an exception may be made to allow inpatient use of leuprolide subcutaneous (Eligard) 7.5 mg for treatment of prostate cancer, if indicated.
See HERE for more information and workflow.
See HERE for additional pharmacy workflow details.
See PREPARATION, MIXING AND ADMINISTRATION OF ELIGARD: HERE